Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 21;36(7):1947–1950. doi: 10.1038/s41375-022-01592-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022, corrected Publication 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — 1-A Patients stratification into IPSS-R risk categories. H-MDS are represented in shades of blue (with light blue stating for very low risk and dark blue stating for very high risk categories); n-MDS are represented in shades of green (with light green stating for very low risk and dark green stating for very high risk categories). In detail, h-MDS were distributed as follows: 15.5% Very Low, 35.1% Low, 30.1% Intermediate, 11.3% High, 8% Very High. N-MDS patients were classified as: 12.8% Very Low, 37.2% Low, 23.1% intermediate, 15.5% High, 11.4% Very High. 1-B Kaplan–Meier curves showing OS in the entire MDS cohort (left panel), LR-MDS (central panel) and HR-MDS (right panel), comparing h-MDS (in blue) vs n-MDS (in green). Vertical lines denote censored patients. Median OS is significantly higher in LR h-MDS as compared to LR n-MDS (central panel, 125 vs 74 months, p < 0.001). Note: h-MDS, hypocellular myelodysplastic syndromes; HR high-risk; LR low-risk; n-MDS normo-/hypercellular myelodysplastic syndromes; OS overall survival.